Tenaya Therapeutics, Inc. (TNYA): Operating Cash Flow
-$68.26M
Year ended 2025-12-31
-$52.33M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$68.26M | n/m | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | -$90.50M | n/m | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | -$102.07M | n/m | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | -$104.42M | n/m | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | -$60.81M | n/m | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | -$35.45M | n/a | 2022-03-23, From 2020-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) | 2025-12-31 | -$68.26M | n/m |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | -$129.79M | n/m |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $29.61M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$47.84M | n/m |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | -$65.84M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $31.63M | -36.2% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | -$10.85M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | -$76.75M | n/m |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | -$131.08M | n/m |
Compare TNYA, INBX, BDTX, IMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗